Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

@article{Herrin2014ComparisonOA,
  title={Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.},
  author={Douglas M Herrin and Emily Coates and Pamela J M Costner and Troy J. Kemp and Martha C. Nason and Kapil K. Saharia and Yuanji Pan and Uzma N Sarwar and Lasonji Holman and Galina Yamshchikov and Richard A. Koup and Yuk Ying S Pang and Robert A. Seder and John T. Schiller and Barney S. Graham and Ligia A. Pinto and Julie E. Ledgerwood},
  journal={Human vaccines & immunotherapeutics},
  year={2014},
  volume={10 12},
  pages={3446-54}
}
Two HPV virus-like particle (VLP) vaccines, HPV-16/18 (GlaxoSmithKline, Cervarix®) and HPV-6/11/16/18 (Merck, Gardasil®), are currently licensed in the United States. Given the similar antigenic content but different adjuvant formulations in the 2 vaccines, they provide an efficient method for evaluating adjuvants and comparing the kinetics of the innate and adaptive immune responses. We randomized women to receive either Cervarix® or Gardasil®, followed 6 month vaccination delivery schedules… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 20 times over the past 90 days. VIEW TWEETS